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Abstract 
In nanomedicine, the hydrophobic nature of paclitaxel has favored its incorporation into many 
nanoparticle formulations for anti-cancer chemotherapy. At lower doses taxanes are reported to 
elicit anti-angiogenic responses. In the present study, the facile synthesis, development and 
characterization of a new lipase-labile docetaxel prodrug is reported and shown to be an effective 
anti-angiogenic agent in vitro and in vivo. The Sn 2 phosphatidylcholine prodrug was stably incor-
porated into the lipid membrane of αvβ3-integrin targeted perfluorocarbon (PFC) nanoparticles 
(αvβ3-Dxtl-PD NP) and did not appreciably release during dissolution against PBS buffer or plasma 
over three days. Overnight exposure of αvβ3-Dxtl-PD NP to plasma spiked with phospholipase 
enzyme failed to liberate the taxane from the membrane until the nanoparticle integrity was 
compromised with alcohol. The bioactivity and efficacy of αvβ3-Dxtl-PD NP in endothelial cell 
culture was as effective as Taxol® or free docetaxel in methanol at equimolar doses over 96 hours. 
The anti-angiogenesis effectiveness of αvβ3-Dxtl-PD NP was demonstrated in the Vx2 rabbit model 
using MR imaging of angiogenesis with the same αvβ3-PFC nanoparticle platform. Nontargeted 
Dxtl-PD NP had a similar MR anti-angiogenesis response as the integrin-targeted agent, but mi-
croscopically measured decreases in tumor cell proliferation and increased apoptosis were de-
tected only for the targeted drug. Equivalent dosages of Abraxane® given over the same treatment 
schedule had no effect on angiogenesis when compared to control rabbits receiving saline only. 
These data demonstrate that αvβ3-Dxtl-PD NP can reduce MR detectable angiogenesis and slow 
tumor progression in the Vx2 model, whereas equivalent systemic treatment with free taxane had 
no benefit. 
Key words: lipase-labile docetaxel prodrug, perfluorocarbon, nanoparticles  
Introduction 
Paclitaxel is a cytoskeletal drug that interacts 
with tubulin to corrupt mitotic spindle assembly, 
chromosome segregation, and cell division by inhib-
iting microtubule disassembly. As a consequence, 
chromosomes are unable to achieve proper metaphase 
configuration and mitotic progression is blocked. The 
inability to complete cell division promotes apoptosis 








The rarity of paclitaxel, initially isolated from the Pa-
cific yew, led to synthetic chemical pathway devel-
opment from which emerged docetaxel, a close 
chemical analogue of the index compound with simi-
lar biological properties. Taxanes have found clinical 
applications as a cytotoxic cancer chemotherapeutic 
[1] as well as a stent-delivered inhibitor of restenosis 
following angioplasty. [2] In nanomedicine, the hy-
drophobic nature of paclitaxel has favored its incor-
poration into many nanoparticle formulations, in-
cluding into the phospholipid outer membrane of 
perfluorocarbon nanoparticles. [3] 
Perfluorocarbon (PFC) nanoparticles have been 
targeted to a myriad of epitopes for diagnostic imag-
ing and site-specific drug delivery for applications in 
atherosclerosis, restenosis, cancer and rheumatoid 
arthritis. [4-7] Early comparisons of hydrophobic 
drugs, including doxorubicin, paclitaxel, and fum-
agillin, revealed that fumagillin, a potent an-
ti-angiogenic mycotoxin, was retained best in disso-
lution studies and was effective in vivo. [8, 9] Unfor-
tunately, fumagillin is not readily available in large 
quantities, and it is photochemically unstable. [10-12] 
Taxanes are reported to elicit potent anti-angiogenic 
effects, particularly at low doses, and the compounds 
are readily available and chemically stable. [13]  
Preliminary studies in the Vx2 model showed 
that paclitaxel incorporated into the outer lipid 
membrane of PFC nanoparticles was not effective for 
anti-angiogenesis whereas fumagillin was. [14] (Ad-
ditional file 1: Supplemental Figure 1) In vivo phar-
macokinetic studies revealed that both fumagillin and 
paclitaxel included in the PFC nanoparticle lipid 
membrane were significantly lost in circulation en 
route to the endothelial target cells, with the prema-
ture release of the taxane occurring quicker and to a 
greater extent than the more hydrophobic fumagillin.  
We have reported effective in vivo delivery of 
hydrophobic drugs entrapped in the phospholipid 
surfactant through a mechanism, we described as 
“contact facilitated drug delivery” (CFDD). [9] Teth-
ering of the nanoparticle to the target cell surface fa-
cilitated the interaction and hemifusion of the two 
lipid membranes, which affords the passive transfer 
of the drug and phospholipids from the nanoparticle 
surface to the outer leaflet of the target cell membrane. 
The drug is then translocated to the inner leaflet 
through an ATP dependent mechanism. [15, 16] 
CFDD eliminates the need for particle internalization 
with subsequent endosomal drug payload escape or 
extracellular particle release with diffusion into the 
cell. We hypothesized that a phospholipid prodrug 
approach that couples the active pharmaceutical in-
gredient (API) through the Sn 2 acyl position (i.e., 
stereospecific hydroxyl group of the second carbon of 
glycerol) would provide a stable membrane complex 
in the nanoparticle during circulatory transit to the 
target site. Subsequent transfer of the monolayer 
components into the target cell membrane would al-
low cell surface or cytosolic phospholipases to enzy-
matically cleave the Sn 2 ester and release the drug, 
allowing it to diffuse into the cytosol for effect. (Fig-
ure 1) 
 
Figure 1. Schematic representation of the concept of the lipase-cleavable Sn 2 phosphatidylcholine docetaxel prodrug: The lipophilic docetaxel prodrug is incorporated into the 
phospholipid surfactant, where the drug enters the protective hydrophobic acyl layer. The active pharmaceutical ingredient (API) is protected from premature dissolution into 
serum or serum lipase liberation during circulation to the target. The API is delivered to the target cell through a “contact facilitated drug delivery” (CFDD) mechanism wherein 
the prodrug exchanges passively into the outer target cell leaflet. The prodrug transfers through an ATP dependent mechanism into the inner cell membrane leaflet, which is 
contiguous with the internal cell membranes (except the mitochondria). The prodrug undergoes a region-selective enzymatic cleavage at the Sn 2 site by phospholipases, such as 
phospholipase A-2 (PLA-2), but up to 60 endothelial lipases could functionally participate in drug liberation into the cytosol. 




The objectives of the present work were: 1) to 
develop and characterize an Sn 2 lipase-labile prodrug 
of docetaxel (Dxtl-PD); 2) to demonstrate the stability 
of the taxane prodrug in the PFC nanoparticles in the 
presence of serum and excess lipase, 3) to demonstrate 
the anti-neovascular efficacy of the agent in the rabbit 
Vx2 cancer model using magnetic resonance (MR) 
angiogenesis molecular imaging, 4) to demonstrate 
the efficacy advantage of the integrin-targeted 
Dxtl-PD nanoparticle compared with the molar 
equivalent dose of Abraxane® given systemically, 5) to 
microscopically characterize the impact of targeted 
Dxtl-PD on intratumoral apoptosis and cell prolifera-
tion.  
Materials and Methods 
Sn 2 lipase-labile taxane phosphatidylcholine 
prodrug synthesis 
 Docetaxel (AvaChem Scientific), a clinically rel-
evant broad-spectrum anticancer agent, was utilized 
in the present study for site-specific anti-angiogenesis 
therapy. Docetaxel has a low solubility in water (<0.1 
μg/ml) and from the synthetic stand point, chemis-
tries involving esterification of the 2’-hydroxyl group, 
which is the most reactive of the hydroxy groups, is 
feasible. Any conventional method of protecting a 
hydroxy group, such as esterification, can be utilized 
to protect this hydroxy group at the 2' position, while 
leaving the hydroxy groups at the 7 and 10 positions 
free for reaction. For the synthesis of docetaxel pro-
drug, several coupling methods were attempted that 
included dicyclohexyl carbodiimide (DCC) / dime-
thylaminopyridine (DMAP), phosphorous pentachlo-
ride (PCl5), and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide/dimethylaminopyridine (EDCI/ 
DMAP). A summary of those results are consolidated 
into Figure 2. Among these reagents, EDCI/DMAP 
was the most efficient approach and produced the 
desired compound in 78% yield. (Figure 3) The com-
pound was isolated and purified by preparative thin 
layer chromatography (prep-TLC) and the structure 
was confirmed by NMR and ESI MS spectroscopy. 
Paclitaxel prodrug (Kereos, Inc., St. Louis, MO) was 
prepared analogously as illustrated and described in 
the Additional file 1: Supplemental Figure 2. 
Of note, specific 2’-modification of docetaxel was 
drawn from analogy based on the scientific literature 
when 1H-NMR spectroscopic studies to confirm the 
conjugation at the 2’ position failed to resolve the 
overlapping resonating peaks from the neighboring 
protons of the tetracyclic 17-carbon (heptadecane) 
skeleton. [17] Further, the initial approach to synthe-
size Dxtl-PD involved coupling chemistries through 
deprotected 3’-NH2 group. (Figure 2) Docetaxel was 
subjected to hydrolytic deprotection in presence of 
formic acid to produce 3’-amine deprotected docet-
axel. However, the attempted conjugation of 
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine 
(PAz-PC) through the free amine group resulted in a 
complex mixture of products and the desired com-
pound was never isolated.  
 
 
Figure 2. Summary of the attempted synthetic approaches to docetaxel phosphatidylcholine prodrug. 
 





Figure 3. Sn 2 Docetaxel Prodrug. (A) Cleavage sites of phospholipase enzymes, PLA2 regiospecifically recognizes the Sn 2 acyl bond of phospholipids; (B) predicted mechanistic 
pathways of hydrolysis catalyzed by PLA2; (C) structure of the docetaxel prodrug synthesized in this work; (D) structure of parent molecule docetaxel and depicting different 
sites for functionalization and activity. PLA2 = phospholipase A2, PLA1=phospholipase A1. 
 
ανβ3-integrin antagonist homing ligand 
 The ανβ3-integrin antagonist was a quinalone 
nonpeptide developed by Bristol-Myers Squibb Med-
ical Imaging (US patent 6,511,648 and related patents) 
and initially reported and characterized as the 
111In-DOTA conjugate RP478 and cyan 5.5 homologue 
TA145 [18]. PFC nanoparticles present ~300 lig-
ands/particle with an IC50 of 50 pM for the 
Mn2+-activated αvβ3-integrin (unpublished data from 
Kereos, Inc., St. Louis, MO, USA). Targeting of the 
lipid-nanoparticles with this peptidomimetic was 
shown to be specific for neovascular endothelial cells 
expressing the αvβ3-integrin, PECAM, but not Tie-2 (a 
maturity biomarker of stabilized endothelium). [19] 
Perfluorocarbon nanoparticle synthesis 
incorporating docetaxel-prodrug 
Phospholipid-encapsulated perfluorocarbon 
(PFC) nanoparticles (NP) were prepared as a micro-
fluidized suspension of 20% (v/v) perfluoroctylbro-
mide (Exfluor Inc., Round Rock, TX), 2.0% (w/v) of a 
surfactant co-mixture, and 1.7% (w/v) glycerin in pH 
6.5 carbonate buffer. The surfactant co-mixture of 
nanoparticles included: ~ 97.6 mole% lecithin, 0.15 
mole% of αvβ3-ligand conjugated lipid and 2 mole% 
(3.75 wt%) of the taxane prodrug. An αvβ3-integrin 
antagonist coupled to phosphatidylethanola-
mine-PEG2000 was used for homing angiogenesis. For 
MR imaging, the surfactant excluded the taxane pro-
drug but included 20 mole% gadolini-
um-DOTA-amide-caproyl-phosphoethanolamine at 
the expense of equimolar substitution of phosphati-
dylcholine in the surfactant commixture (i.e., 
αvβ3-Gd-DOTA NP). Nontargeted (NT) nanoparticles 
excluded the homing ligands. The surfactant compo-
nents for each formulation were combined with the 
perfluorocarbon, buffer, and glycerin with pH ad-
justed to 6.5, and the mixtures were homogenized at 
20,000 psi for 4 minutes. The nanoparticles were pre-
served under inert gas in sterile sealed vials until use. 
Upon completion of the synthesis, nanoparticles were 
thoroughly characterized by physical-chemical tech-
niques e.g. dynamic light scattering (DLS), electro-
phoretic potential (zeta) and transmission electron 
microscopy (TEM). A typical preparation of 
αvβ3-Dxtl-PD NP resulted in: particle size, 214±20 nm; 
zeta potential, (ζ) -23±12 mv; and polydispersity in-
dex, 0.15±0.5. (Figure 4a,b) 
Comparison of docetaxel, docetaxel-prodrug, 
paclitaxel, and paclitaxel-prodrug on 
endothelial cell proliferation in vitro 
Mouse vascular endothelial cells (2F2B) were 
plated at 2500 cells/well in media with Angiotensin II 
(1nM) for overnight culture at 37°C, 5% CO2. Cells 
were treated with paclitaxel, docetaxel, paclitaxel 
prodrug, or docetaxel prodrug at 0.5 µg/ml, 1 µg/ml, 




5 µg/ml, 10 µg/ml, 50 µg/ml and 100 µg/ml for 1 
hour with mild agitation. The treatments were re-
moved; cells were washed three times with PBS; fresh 
media was added; and the plates were returned back 
to the incubator. Cell proliferation was assayed at 24, 
48, and 72 hours. At each time point, 20 µl of Alamar 
Blue was added to each well and incubated for 4 
hours. The supernatants were transferred to a new 
replicate plate for spectroscopic analysis. The original 
wells were replenished with fresh media and all 
plates were returned to the incubator until the next 
time point. The reaction was monitored using a fluo-
rescence plate reader (λex 570nm, λem 585nm) where 
the resulting signal is proportional to the number of 
viable cells present. Signal intensity from each sample 
was normalized to signal from the positive saline 
control. Each treatment was replicated three times.  
In vitro dissolution stability of 
docetaxel-prodrug in PFC nanoparticles 
 The stability of the Dxtl-PD incorporated at 2 
mole% (3.75 wt%) into the surfactant (360mg) of PFC 
nanoparticles was evaluated by dissolution in plasma 
and buffer over three days in triplicate. Drug-laden 
nanoparticles were secured within dialysis tubing 
(MWCO=60K, Spectrum Laboratories, Inc.), which 
were washed externally to remove possible surface 
contamination, and then incubated in 3.5 ml of human 
plasma at 37°C for 3 days with constant slow rotation. 
The dialysis tube samples were transferred to 3.5 ml 
of fresh plasma daily and 200µl of the 3.5 ml dialysate 
was injected into a reversed-phase HPLC system 
(Waters 600S controller, 626 delivery pump, 717 auto 
sampler, and 2487 Dual λ absorbance detector) 
through a 0.2 µm syringe filter for analysis of prodrug 
release. Dxtl-PD was detected at a wavelength 227 
nm. A Grace Vydac C18 column, 4.6 x 250 mm, was 
used with a mobile phase consisting of: (A) 80% ace-
tonitrile, 20% methanol and (B) 100% 0.2 M ammo-
nium acetate, pH 4.5 using gradient conditions (from 
100% A to 40% A 60% B within 30 min then returning 
to 100% A in 5 min for an additional 5 min (run time 
40 min; drug retention time ~33 min). Flow rate was 1 
ml/min.  
 To further assess the potential susceptibility of 
Dxtl-PD in PFC nanoparticles to premature lipase 
liberation, drug-laden nanoparticles (250 µl) were 
incubated for 24 hours with 3.5 ml fresh plasma or 
fresh whole blood preserved with EDTA each spiked 
with 250 µl 0.9 % NaCl, 15-30 mM CaCl2 and 0.278 mg 
phospholipase A2. This was referenced to an 
equimolar amount of Dxtl or Dxtl-PD in DMSO di-
luted in 3.5ml of PBS pH 7.4. The samples were con-
tinuously agitated on a nutator to prevent settling. As 
a positive control, 250 µl 2-propanol was added to the 
lipase-spiked plasma containing Dxtl-PD in PFC na-
noparticles to “crack” the emulsion’s integrity, ex-
posing the lipase-labile prodrug to the enzyme-rich 
plasma milieu. The plasma-enzyme-NP mixture (250 
µl) was combined with 250 µl Cleanascite™ for lipid 
removal and clarification (Biotech Support Group, 
Inc., Monmouth Junction, NJ) at 25°C for 15min. The 
mixture was centrifuged at 5000 rpm (30 min) and the 
supernatant (200 µl) was analyzed by HPLC.   
 To determine the potential exchange of Dxtl-PD 
from the nanoparticle surfactant to erythrocyte 
membranes, 2-propranolol (200 µl) and water (200 µl) 
were added to the erythrocyte aliquot (100 µl) and the 
mixture was centrifuged at 1000 rpm for 10 min. The 
RBC fraction was separated from the pelleting PFC 
nanoparticles (specific gravity of 2). The RBC fraction 
was analyzed in triplicate for the Dxtl-PD and its 
major metabolites by HPLC. 
Docetaxel-prodrug testing in vitro: 
cytotoxicity and metabolic assays 
 Mouse endothelial cells (2F2B; ATCC® 
CRL2168™, Manassas, VA) were seeded on a 96 well 
plate (2000-5000 cells/well) in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with 4.5 g/L glucose; 
L-glutamine; and 10% heat-inactivated fetal bovine 
serum plus 10 µM angiotensin II (Sigma Chemical Co, 
St. Louis, MO) and incubated at 37ºC with 5% CO2. 
After 24 hours, cells were incubated for 1 hour with 1) 
αvβ3-Dxtl-PD NPs, 2) equimolar equivalent of Taxol® 
(0.3 µM), 3) αvβ3-No drug NPs, or 4) saline. After in-
cubation the wells were washed three times with PBS 
and returned to the incubator. At 96 hours after drug 
exposure, cell proliferation was measured using the 
MTT assay for cytotoxicity, which measures the ac-
tivity of cellular enzymes that reduce the tetrazolium 
dye, MTT, to the insoluble formazan (Invitrogen; 
Carlsbad, CA, USA). Each treatment was replicated 6 
times. 
 In a confirmatory experiment using human en-
dothelial cells (HUVEC; Lonza Walkersville, MD, 
USA), cell metabolic activity was assessed using a 
Vybrant Cell Metabolic Assay Kit (Invitrogen). The 
experiment was conducted as described above with 6 
replicates/treatment and measurements assessed at 
48, 72, and 96 hours. The treatments applied were: 
αvβ3-Dxtl-PD NPs, free Dxtl in methanol (0.3 µM) and 
αvβ3-No drug NPs. This assay is based on the reduc-
tion of non-fluorescent C12-resazurin to 
red-fluorescent C12-resorufin in metabolically active 
cells, which is attributed to different oxido-reductase 
enzyme systems that use NAD(P)H as the primary 
electron donor. The redox reaction was monitored 
using a fluorescence plate reader (λex 570nm, λem 
587nm) where the resulting signal is proportional to 




the number of viable cells present. Signal intensity 
from each sample was normalized to signal from the 
positive control (αvβ3-targeted no drug nanoparticles).  
Docetaxel-prodrug evaluation in rabbit Vx2 
tumor angiogenesis model 
All animal studies were conducted in accordance 
with a protocol approved by the Washington Univer-
sity Animal Studies Committee.  
Surgical preparation  
 The anti-angiogenesis effects of Dxtl-PD were 
evaluated in the Vx2 rabbit tumor model using MR 
angiogenesis imaging and histology. Male New Zea-
land White rabbits (~2 kg) were anesthetized with 
intramuscular ketamine and xylazine. One hind leg 
was shaved, prepped under sterile conditions, and 
infiltrated with Marcaine. A 2-3 mm3 rabbit Vx2 tu-
mor fragment (squamous cell carcinoma, National 
Cancer Institute Tumor Repository, Frederick, MD, 
USA) was implanted at a depth of approximately 0.5 
cm through a small incision into the popliteal fossa. 
Anatomical planes were closed and secured with a 
single absorbable suture. The skin was sealed with 
Dermabond skin glue. Animals were recovered by 
reversing the effect of ketamine and xylazine with 
yohimbine.  
Experimental Design 
 On days 9, 12 and 15 post tumor implantation, 
rabbits were treated with either: αvβ3-Dxtl-PD NP, 
non-targeted Dxtl-PD NPs, or αvβ3-targeted no drug 
NPs at a 2ml/kg i.v. dose. On day 17, rabbits were 
imaged in a clinical 3T MR scanner (Philips Achieva) 
with an 8-element SENSE coil using a high-resolution, 
T1-weighted, fat suppressed, 3D gradient echo se-
quence (TR/TE = 42/5.7ms, 45o flip angle, 2 NSA, 0.25 
x 0.25 x 0.5 mm resolution). Images were obtained 
before and 3 hours after i.v. administration of 
αvβ3-Gd-DOTA NP (1ml/kg) to compare the influ-
ence of the three treatments on angiogenesis. At each 
time point, rabbits were anesthetized with 1% to 2% 
Isoflurane in oxygen to effect. In a second cohort of 
rabbits (n=4/group), the anti-angiogenesis effect of 
serially administered Abraxane® at the same drug 
dose and days of treatment described above were 
compared to an analogously treated saline control. 
MRI molecular imaging of tumor volumes and angi-
ogenesis as well as image post processing were per-
formed as described. 
Image analysis 
 In each experiment, the signal intensities of the 
MR images were analyzed with MATLAB software 
(The Math Works, Natick, MA, USA). Dynamic 
T1-weighted signal intensities were normalized to a 
Gd-DTPA doped water reference standard included 
within each imaging field-of-view. For each animal, a 
region-of-interest (ROI) was manually placed around 
the tumor edge on each baseline slice, and the stand-
ard deviation of the average tumor signal at baseline 
was calculated. Voxels on post-injection MRI images 
were defined as enhanced if the signal intensity ex-
ceeded the mean tumor signal at baseline by more 
than three standard deviations. The tumor ROI was 
automatically partitioned into a rim and core region 
using an automated erosion method developed in 
MATLAB. The core region was set to approximately 
half of the ROI volume. The volume of enhancement 
was calculated, as well as the relative distribution of 
enhancing voxels in the periphery versus the core of 
the tumor. High-resolution 3D tumor reconstructions 
were created in MATLAB to map the spatial distribu-
tion of enhancing neovasculature in each treatment 
group. The overall 3D structure of the tumor was 
displayed as a mesh surface plot using isosurface 
rendering and a smoothing filter. A surface plot of the 
enhancing voxels was reconstructed similarly, and 
overlaid onto the tumor volume. 
Histology  
 Immediately after MR imaging, animals were 
euthanized, and tumors were resected, weighed, and 
frozen in optimum cutting temperature (OCT) com-
pound. Tumors (n=4/treatment group) were sec-
tioned and stained for cell proliferation (proliferating 
cell nuclear antigen, PCNA) antibody; Abcam, Cam-
bridge, MA, USA) and apoptosis (TUNEL assay; 
Promega, Madison, WI, USA) to corroborate MR re-
sults. Microscopic images (40x) were obtained with an 
Olympus BX61 microscope, Color-view CCD Camera 
and analyzed with ImageJ software using manual 
placement of regions of interest on each microscopic 
image (National Institute of Mental Health, Bethesda, 
Maryland, USA.). 
Statistical Analysis 
 Data were analyzed using analysis of variance 
(SAS Inc.; Cary, NC, USA) (p < 0.05). Data are pre-
sented as the mean ± standard error of the mean un-
less otherwise stated. 
RESULTS 
Stability of docetaxel-prodrug in 
perfluorocarbon nanoparticles during 
dissolution 
 The retention of the Dxtl-PD in the PFC nano-
particle during in vitro dissolution over 3 days in PBS 
with albumin or human plasma was excellent with < 
6% of prodrug released, indicating that the drug was 
sufficiently membrane stable. (Figure 4c) Phospho-




lipases A2 (PLA2s) EC 3.1.1.4, commonly found in 
mammalian tissues, specifically recognizes the Sn 2 
acyl bond of phospholipids and regioselectively hy-
drolyzes the bond, releasing free fatty acid and lyso-
phospholipids. The catalytic mechanism of PLA2 is 
presumably initiated by a His-48/Asp-99/calcium 
complex within the active site in the presence of cal-
cium or other small cations like cobalt and nickel. A 
simplistic mechanism of catalytic action of PLA2 on 
Dxtl-PD has been proposed in Figure 3. Figure 4d 
illustrates the HPLC reference retention time of 
Dxtl-PD (~32min). In the presence of excess lipase, 
Dxtl-PD nanoparticles had nearly negligible release of 
the drug (Figure 4e). Incubation of the Dxtl-PD na-
noparticles in whole blood under slow continuous 
agitation revealed that the prodrug was not passively 
transferred to erythrocytes by transient contact (Ad-
ditional file 1: Supplemental Figure 3). Supple-
mental Figure 4 shows the relative retention times of 
free docetaxel, Dxtl-PD, and the metabolism of 
Dxtl-PD in methanol added to phospholipase en-
riched plasma. As expected, docetaxel retention was 
somewhat less than the HPLC retention of Dxtl-PD. 
When Dxtl-PD was added to lipase rich plasma, 
docetaxel was liberated and differentiated from the 
parent prodrug. Regioselective hydrolysis of the pro-
drug by lipase in vitro required the addition of 
2-propranol to “crack” the nanoparticle and expose 
the membrane components to the enzyme. The ap-
pearance of multiple peaks around 30 minutes 
showed that the Dxtl-PD was released and hydro-
lyzed from the prodrug backbone. (Figure 4f) While 
the 32.5 minutes corresponded to intact Dxtl-PD, the 
peak at 26.5 minutes in the presence of enzyme was 
confirmed by MS to be a hydrolyzed product, baccatin 
III [m/z 524 (M+Na)], (Figure 3). The cleavage of the 
side chain at C-13 of the taxane ring is known in the 
literature and also results in the formation of baccatin 
III in rats and is formed as a minor species in humans. 
[20, 21]  
 Collectively, these results suggest that Dxtl-PD 
is snuggled into the hydrophobic membrane and 
protected from hydrolysis and lipase activation in 
plasma until the nanoparticle is destabilized, such as 
with alcohol. Over the relatively brief time course of 
systemic targeting, αvβ3-Dxtl-PD NP retention of drug 
is anticipated to be very high, as opposed to earlier 
results with free paclitaxel dissolved into the surfac-
tant, with negligible passive transference to 
co-circulating erythrocytes.  
 
 
Figure 4. Characterization of docetaxel prodrug (Dxtl-PD) loaded PFC nanoparticles (NP). (A) Number-averaged hydrodynamic diameter distribution of αvβ3-Dxtl-PD in 
hydrated state; (B) transmission electron microscopy (TEM) image of the integrin targeted nanoparticles (scale bar: 200 nm); (C) dissolution of Dxtl-PD over 3 days when 
incubated in PBS with albumin (red) or human plasma (green); HPLC traces of Dxtl-PD (D), Dxtl-PD-NP treated with PLA2 (E) and Dxtl-PD-NP “cracked” with isopropanol and 
exposed to PLA2. PLA2=phospholipase A2. 





Figure 5. Mouse vascular endothelial cells (2F2B) stimulated with angiotensin II 
(1nM) were treated with paclitaxel, docetaxel, paclitaxel prodrug, or docetaxel 
prodrug at 0.5 µg/ml, 1 µg/ml, 5 µg/ml, 10 µg/ml, 50 µg/ml and 100 µg/ml for 1 hour. 
Cultures were monitored for proliferation at 24, 48, and 72 hours. No difference (p= 
NS) in biopotency of the different taxane forms was detected. 
Bioequivalence of docetaxel, paclitaxel, 
docetaxel prodrug, and paclitaxel-prodrug 
 The bioequivalence of paclitaxel, docetaxel, 
paclitaxel prodrug, or docetaxel prodrug at 0.5 µg/ml, 
1 µg/ml, 5 µg/ml, 10 µg/ml, 50 µg/ml and 100 µg/ml 
was studied in angiotensin II stimulated mouse vas-
cular endothelial cells (2F2B). Monitoring of the pro-
liferative response of these endothelial cells to the 
varying doses of drugs at 24, 48 and 72 hours post 
exposure reveal no significant difference in an-
ti-endothelial cell proliferation. (Figure 5) 
In vitro cytotoxicity and metabolic assays 
 The cytotoxicity of Dxtl-PD incorporated into 
PFC NPs was compared to Taxol® in vitro using 2F2B 
endothelial cell cultures stimulated with angiotensin 
II to up-regulate activated αvβ3-integrin expression. 
αvβ3-Dxtl-PD NPs decreased (p<0.05) cell prolifera-
tion 34% at 96 hours compared to the saline control, 
showing that the drug retained bioactivity through 
the prodrug synthesis, and that the compound was 
effectively transferred from the particle, into the cell 
membranes from where it was liberated in adequate 
concentrations to induce cell cytotoxicity. (Figure 6a) 
The αvβ3-no-drug NPs had no effect on cell prolifera-
tion. At the equivalent low dose of taxane, the Taxol® 
treatment decreased cell proliferation less, 8%, which 
was more similar to the controls but not significantly 
less than the αvβ3-Dxtl-PD NP. The slightly greater 
effectiveness of the Dxtl-PD is related to the number 
of drug laden nanoparticles bound to the endothelial 
cells through the integrin receptor within the brief 
incubation window versus the amount of free 
paclitaxel able to permeate the cell. (Figure 6a) 
 
 
Figure 6. A) Cell proliferation via MTT assay comparing docetaxel prodrug targeted to angiotensin II activated integrin receptor in 2F2B endothelial cells versus Taxol® and no 
drug targeted particles. At 96 hours, the prodrug was significantly (p < 0.05) more effective than the control and at least equivalent to Taxol®. B) Cell proliferation via Vybrant 
Cell Metabolic Assay comparing docetaxel prodrug in HUVEC endothelial cells versus docetaxel in methanol and no drug targeted particles. Marked and equivalent reductions 
in cell proliferation were appreciated at 48, 72, and 96 hours with free drug and the integrin targeted Dxtl-PD NPs. * p<0.05. 
 
 




 In a follow up experiment using angiotensin II 
stimulated HUVEC cells, cell metabolic activity re-
sponses to nanoparticle delivered docetaxel were as-
sessed at earlier time points: 48, 72, and 96 hours. 
(Figure 6b) In this experiment native docetaxel in 
methanol added to the medium was compared to its 
integrin targeted lipase-labile prodrug analog on an 
equimolar drug basis. The treatments applied were: 
αvβ3-Dxtl-PD NPs, free Dxtl, and αvβ3-no drug NPs. 
As shown in Figure 6b, the nanoparticle delivered 
docetaxel prodrug or parent compound equivalently 
decreased (p<0.05) cell metabolic activity at 48 hours 
when compared with the targeted no-drug nanopar-
ticle control. The marked reductions in cell metabolic 
activity persisted for both drug forms at 72 and 96 
hours. These results substantiate the comparable bi-
oequivalence of the native docetaxel and targeted Sn 2 
lipase-labile prodrug in angiotensin II activated en-
dothelial culture. These data further suggest that the 
intracellular enzymatic hydrolysis requirement to 
achieve efficacy of Dxtl-PD was not limiting in the 
activated HUVEC cells.  
Docetaxel prodrug evaluation in rabbit Vx2 
tumor angiogenesis model 
 In a previously unpublished pilot study, the ef-
fectiveness of paclitaxel incorporated into the mem-
brane of αvβ3-targeted PFC nanoparticles was evalu-
ated in the Vx2 tumor model (Additional file 1: Sup-
plemental Figure 1). The results showed that serial 
doses of the agent produced neither anti-neovascular 
nor anti-tumor benefit when evaluated by MR mo-
lecular imaging with αvβ3-paramagnetic PFC nano-
particles. Studies simultaneously tracking the per-
fluorocarbon core, paclitaxel, and homing ligand in 
whole blood from rats showed that the particles were 
intact but the drug was rapidly and prematurely loss 
from the lipid membrane (Kereos, St. Louis, un-
published data). 
In the present study, the efficacy of the docetaxel 
Sn 2 prodrug incorporated into the lipid membrane of 
αvβ3-targeted PFC nanoparticles (αvβ3-Dxtl-PD NP) 
was compared in the Vx2 rabbit tumor model to 
non-targeted Dxtl-PD NPs (NT-Dxtl-PD NP) and 
αvβ3-No Drug NPs. Animals were serially treated on 
days 9, 12, and 15 days post implant. On day 17, rab-
bits were imaged in a clinical 3T MR scanner (Philips 
Achieva) using a high-resolution, T1-weighted, fat 
suppressed, 3D gradient echo sequence at baseline 
and 3 hours after i.v. administration of 
αvβ3-Gd-DOTA nanoparticles (1ml/kg), previously 
characterized and demonstrated in vivo.  
As previously reported, angiogenesis contrast in 
the control animals was concentrated in the tumor 
periphery with minimal signal enhancement localized 
to the core, except for the rare lobulated tumor with 
an internal segment of neovascular-rich capsule. 
(Figure 7a,c,d) The peripheral distributions of con-
trast-enhanced voxels (i.e., 3 standard deviations 
greater than baseline) in the control were typically 
confluent and asymmetrically distributed, presuma-
bly reflecting the most active regions of tumor growth 
at the time of imaging. αvβ3-Dxtl-PD NPs substan-
tially decreased (p<0.05) MR detectable angiogenesis 
in the Vx2 tumor model after serial treatment, as op-
posed to the negative results achieved previously 
with the targeted particles incorporating native 
paclitaxel. (Figure 7b,c,d) The magnitude of neovas-
cular suppression achieved with NT-Dxtl-PD NP was 
similar to the results obtained with αvβ3-Dxtl-PD NP, 
suggesting that the passive entrapment of the fre-
quently dosed NT-Dxtl-PD NP within the irregular 
neovascular bed provided enough sustained parti-
cle-endothelial cell contact to afford prodrug transfer, 
at least to the extent detectable by MR molecular im-
aging. We have previously shown with dynamic MR 
imaging in the Vx2 rabbit tumor [24] and mouse 
melanoma [25] models, that passive entrapment of 
nontargeted paramagnetic PFC nanoparticles within 
the tumor peripheral neovasculature is detectable 
with approximately half the level of contrast signal 
observed with αvβ3-targeted paramagnetic particles at 
two hours. No differences in tumor volume between 
any treatment group were measured. (Additional file 
1: Supplemental Figure 5) 
To verify that the neovascular effect of the 
Dxtl-PD NP, appreciated by MR molecular imaging, 
was not attributable to the systemic premature release 
of taxanes in one or both groups, a separate cohort of 
rabbits implanted with the Vx2 tumor were treated 
serially with Abraxane® given at an equimolar dose 
and compared to a saline control. MR molecular im-
aging of angiogenesis with αvβ3-Gd-DOTA nanopar-
ticles on day 17 revealed no anti-angiogenic effec-
tiveness in the Abraxane® treated rabbits versus the 
controls. (Figure 8) In fact, the magnitudes of neo-
vascular contrast measured in each group were nearly 
identical, as were the tumor volumes (Additional file 
1: Supplemental Figure 6). These results demonstrate 
that the retention and delivery method of Dxtl-PD in 
the nanoparticle was essential to elicit the MR 
measureable change in tumor neovasculature.  
 





Figure 7. A) T1w MR images of Vx 2 tumor obtained at baseline and 3 hours after αvβ3-Gd-DOTA NP in animals receiving αvβ3-no drug NP showing peripheral tumor 
angiogenesis contrast enhancement false colored in yellow. B) The same image sequence as panel A in Vx2 tumor rabbits following αvβ3-Dxtl-PD NP. C) Histogram illustrating 
marked angiogenesis in the control rabbits rim (tumor peripheral 50%) versus those receiving Dtxl-PD with or without targeting. Note minimal contrast signal with the tumor 
core. Marked decrease in contrast in nontargeted (NT) animal group suggests that the dosage or frequency of treatment was in excess of the therapeutic need with passive 
entrapment providing adequate particle-to-endothelium contact to afford significant anti-angiogenesis. D) Representative 3D neovascular maps of Vx2 tumor in control and 
targeted Dxtl-PD treatment groups. Note asymmetric distribution of confluent neovascular regions in the control rabbit was not appreciated in the treated animal. Blue voxels 




Figure 8. Vx 2 tumor angiogenesis following serial dosages of Abraxane® (equivalent 
to treatment regimen used in Figure 7) versus control rabbits receiving saline as 
assessed by MR molecular imaging with αvβ3-Gd-DOTA NP. No effect of the free 
taxane drug was detected, which was equivalent to the results previously obtained 
with free Taxol® in the preliminary data (Additional file 1: Supplemental Figure 
1). 
 
Histological assessments of tumor showed that 
αvβ3-Dxtl-PD NP decreased (p<0.05) tumor cell pro-
liferation, as assessed by PNCA staining of the lesion. 
(Figure 9c,d) The same trend was measured for tumor 
apoptosis. (Figure 9a,b) In each case, the patterns of 
staining appeared as patchy confluencies, distributed 
variably among animal tumors. These data suggest 
that targeted delivery of Dxtl-PD was biologically 
more effective than NT Dxtl-PD treatment, which is 
consistent with previously reported dynamic imaging 
results discussed above. [24] [25] Further, while MR 
angiogenesis imaging is able to robustly track the 
progression of Vx2 tumor neovasculature around 12 
days post implantation or longer, MR sensitivity may 
permit only assessment of the macroscopic changes of 
neovasculature and may not adequately resolve mi-
croscopic differences in neovasculature which may 
still impart significant tumor biology impact. Changes 
in microvasculature counts following theranostic an-
ti-angiogenesis treatment were correlated previously 
with MR molecular imaging of angiogenesis in ath-
erosclerotic rabbits[26], However, given the extensive 
heterogeneity of angiogenesis presentation in the tu-
mor, replication here would require complete serial 
sectioning and quantification of 
neo/microvasculature to compare the extent of mi-
croscopic angiogenesis persisting with and without 
integrin-targeting, and was precluded in this project. 
 





Figure 9. A) Histogram showing a trend (nonsignificant (NS), p = 0.2) toward increased apoptosis among Vx 2 tumor rabbits receiving αvβ3-Dxtl-PD NP versus controls. B) 
Illustrative sections (40x) of Vx 2 tumor following TUNEL staining (brown arrows) using a methyl green nuclear positive reference for tumor area (green arrows). C). Histogram 
showing a significant (p < 0.05) decrease in proliferation index among Vx2 tumor rabbits receiving αvβ3-Dxtl-PD NP versus controls. D) Representative sections (40x) of Vx2 
tumor following PCNA staining (brown arrows) using a methyl green nuclear positive reference for tumor area (green arrows). * p < 0.05. 
 
Discussion 
 The facile synthesis, development and charac-
terization of a new Sn 2 lipase-labile docetaxel pro-
drug is reported and shown to be an effective an-
ti-angiogenic agent in vitro and in vivo. The Sn 2 
phosphatidylcholine drug stably incorporated into 
the nanoparticle lipid membrane and did not appre-
ciably release during dissolution against PBS buffer or 
plasma over three days. Further, overnight exposure 
of αvβ3-Dxtl-PD NP to plasma spiked with phospho-
lipase enzyme failed to liberate the taxane from the 
membrane, unless the nanoparticle itself was first 
“cracked” with alcohol. The bioactivity and efficacy of 
Dxtl-PD was demonstrated in endothelial cell culture 
and found to be equivalent to docetaxel, paclitaxel, 
and paclitaxel prodrug. The effectiveness of 
αvβ3-Dxtl-PD NP was at least as effective as Taxol® at 
equimolar doses over 96 hours, with 4-fold numerical 
advantage noted for the prodrug over the free com-
pound. At earlier time points, in vitro cell metabolism 
studies demonstrated that free docetaxel had equiva-
lent efficacy to αvβ3-Dxtl-PD NP, indicating that req-
uisite intracellular lipase liberation of docetaxel did 
not limit prodrug effectiveness at 48 hours, and this 
result persisted through 96 hours. The effectiveness of 
αvβ3-Dxtl-PD NP compared with the negative control 
was demonstrated in the Vx2 rabbit model using MR 
molecular imaging of angiogenesis. Nontargeted 
Dxtl-PD nanoparticles had a similar anti-angiogenic 
response as measured with MR molecular imaging, 
indicating that passive entrapment of the particles in 
the tumor neo-/microvasculature was adequate to 
decrease MR detectable neovasculature. However, 
histology of these tumors revealed that αvβ3-Dxtl-PD 
NP impacted tumor progression and apoptosis, which 
was not appreciated for NT Dxtl-PD NP or the control 
groups. Abraxane® given at an equimolar drug dos-




age and frequency as the αvβ3-Dxtl-PD NP had no 
effect on angiogenesis when compared to control 
rabbits receiving saline only, confirming that the ef-
fectiveness of this low taxane exposure was depend-
ent on nanoparticle delivery and concentration at the 
tumor.  
Dxtl-PD was not incorporated into the 
αvβ3-Gd-DOTA nanoparticles to support simultane-
ous imaging and therapy serially as previously re-
ported in other models. [22] In a previous time course 
study characterizing MR angiogenesis mapping in the 
Vx2 tumor on days 9, 12, and 15 post tumor implan-
tation, MR molecular imaging was unable to delineate 
and differentiate a coherent neovascular pattern or 
increased integrated MR contrast signal between 
animals receiving αvβ3-Gd-DOTA PFC NPs or 
NT-Gd-DOTA PFC NPs on day 9. Although angio-
genesis is well known to occur robustly at a micro-
scopic level as tumors grow beyond 2 to 3 mm, the 
insensitivity of MRI, even using a strong molecular 
imaging agent such as αvβ3-Gd-DOTA PFC NP, was 
unable to differentiate specific neovascular targeting 
from passive nontargeted entrapment in the Vx2 tu-
mor neo/microvasculature on day 9 post implanta-
tion. [23] However, on days 12 and 15 of that study, 
clear differences in neovasculature signal were meas-
ured between the two groups and a very close corre-
spondence between the neovasculature pattern de-
termined on day 12 and day 15 in the same animal 
was illustrated. [23] Consequently, the pursuit of 
theranostic MR molecular imaging approach begin-
ning on day 8 post-implantation as a baseline imaging 
reference, as demonstrated in other experimental 
models[22], was precluded and a companion diag-
nostic design with serial treatments followed by ter-
minal imaging measurement was adopted.  
 The direct targeting and delivery of low dose 
docetaxel to nascent endothelial cells is a distinctly 
different mechanism of achieving anti-angiogenesis 
treatment than the vascular endothelial growth factor 
(VEGF) inhibitors approved to date. Certainly, tumor 
angiogenesis is a complex process with a dominant 
role attributed to VEGF. Bevacizumab, anti-VEGF-A, 
was initially intended to block angiogenesis and vas-
cular permeability by adsorbing VEGF-A in the tumor 
milieu. However, VEGF-A is produced not only by 
the tumor but also by surrounding stromal cells, such 
that monotherapy with the drug was unsuccessful. 
Ultimately, bevacizumab was approved as the first 
inhibitor for combination use in metastatic colorectal 
cancer [27], then later for non-squamous, non-small 
cell lung cancer [28], renal cell carcinoma [29], and 
glioblastoma multiforme [30]. Several other 
VEGF-directed drugs have followed which competi-
tively inhibit the intracellular ATP at the catalytic 
binding site of tyrosine kinases, including sunitinib 
(Pfizer), pazopanib (Glaxo-Smith-Kline), sorafenib 
(Nexavar), vandetanib (Astrazeneca), carbozantinib 
(Exelixis), axitinib (Inlyta), and linifanib (Abbott). 
Tyrosine kinase inhibitors (TKI) are designed to 
blockade the downstream signaling pathways that 
promote tumor growth and metastasis when stimu-
lated by angiogenic factors. The third class of current 
anti-angiogenesis inhibitors impact mTOR, mamma-
lian target of rapamycin, which, under upstream con-
trol via the PI3K/AKT pathway, influences cell 
growth by modulating metabolism, protein synthesis, 
and autophagy. Rapamycin and its analogs, temsiro-
limus (CCI-779) and everolimus (RAD001), are allo-
steric inhibitors of mTORC1. In general, these agents 
have had limited effectiveness because they are spe-
cifically directed to mTORC1, and a second mTOR 
(mTORC2) is able to exert negative feedback to 
AKT/PKB that can antagonize the anti-tumor effects 
of the rapalogs. Resistance to all of these drugs may 
result from negative feedback, invocation of alterna-
tive angiogenic pathways that circumvent the block-
ade, selection pressure for tumor or stem cells able 
survive the hypoxic environments, induction of cry-
oprotective tumor cell autophagy or dormancy, or 
tumor extravasation to better environs. The nano-
medicine approach with αvβ3-Dxtl-PD NP is inde-
pendent of how the neovasculature expansion is 
stimulated to occur, and the endothelium, which is a 
normal replicating cell, as opposed to the epigenet-
ically morphing tumor cells, can be anticipated to 
respond uniformly to a directly targeted nanosystem 
approach regardless of the tumor type. As with other 
anti-angiogenesis therapies, αvβ3-Dxtl-PD NP treat-
ment will best be used as an adjuvant combined with 
effective chemotherapy rather than standalone mon-
otherapy. Further, MR molecular imaging, which was 
used in this study to assess anti-angiogenesis re-
sponse, is a robust technique amenable to identifying 
patient populations most likely to have the greatest 
treatment benefit-to-risk ratio and longitudinally 
monitor for recurrence, but it may lack the sensitivity 
required to detect biologically relevant microscopic 
levels of neovascularity that may indicate a complete 
therapeutic response.  
 In the present study, the concept and efficacy of 
using docetaxel as an Sn 2 lipase labile prodrug was 
studied and demonstrated in vitro and in vivo. In con-
tradistinction to the original failed pilot studies pur-
sued with αvβ3-paclitaxel (free) NP, the use of Dxtl-PD 
NPs resulted in significant anti-angiogenesis. Further, 
Abraxane® given in equivalent doses following the 
same treatment regimen was ineffective, emphasizing 
the importance of the targeted drug delivery para-
digm. Whereas some effective nanomedicine applica-




tions are intended to be improved excipients, 
providing more extended drug release in circulation, 
αvβ3-Dxtl-PD NP is an anti-angiogenesis agent that 
concentrates a small amount of systemically admin-
istered taxane directly on the target for a highly po-
tent effect.  
Conclusion 
 The synthesis of the Sn 2 docetaxel prodrug was 
accomplished, which produced a lipophilic prodrug 
incorporated into the phospholipid surfactant of PFC 
nanoparticles. In endothelial cell culture, the biopo-
tency of paclitaxel, docetaxel, paclitaxel prodrug and 
docetaxel prodrug were equivalent. In vitro experi-
ments confirm that the drug was stable in the particle 
membrane in plasma and whole blood, even in the 
presence of excess phospholipase. Prodrug-laden 
particles were bound to target cells, the docetaxel 
prodrug was delivered and equivalently bioactive to 
the parent drug in the same nanosystem. In the Vx2 
cancer model, αvβ3-Dxtl-PD NP elicited strong an-
ti-angiogenesis effects as assessed by MR neovascular 
molecular imaging and histopathology, but acute 
changes in tumor volumes were not appreciated. In 
contradistinction to current anti-angiogenic treat-
ments, for which the intent to blockade or modulate 
tumor production of VEGF can be circumvented or 
ameliorated by countering biochemical mechanisms 
in the epigenetically morphing tumor cells, 
αvβ3-Dxtl-PD NP should deliver uniform an-
ti-angiogenic results regardless of the molecular 
mechanism of neovessel stimulation and may be an 
effective adjuvant to chemotherapies in aggressive 
cancers dependent on an expanding rich neovascula-
ture. 
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Additional File 1:  




CFDD: contact-facilitated drug delivery 
API: active pharmaceutical ingredient 
Dxtl-PD: docetaxel prodrug 
MR(I): magnetic resonance (imaging) 
DCC: dicyclohexyl carbodiimide  
DMAP: dimethylaminopyridine 
PCl5: phosphorous pentachloride  
EDCI: 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide 
NMR: nuclear magnetic resonance 
ESI MS: electron spin ionization mass spectrom-
etry 







TLC: thin layer chromatography 
NP: nanoparticle 
DLS: dynamic light scattering  
Zeta: zeta / electrophoretic potential  
TEM: transmission electron microscopy 
Sn 2: glycerophospholipids use "sn" notation, 
stereospecific numbering. By convention the hydroxyl 
group of the second carbon of glycerol (Sn 2) is on the 
left on a Fischer projection.  
PECAM: platelet endothelial cell adhesion mol-
ecule 
Tie-2: endothelium-specific receptor tyrosine 
kinase 
MWCO: molecular weight cut-off 
HPLC: high performance liquid chromatography 
PEG: polyethylene glycol 
DMEM: Dulbecco’s Modified Eagle’s Medium  
MTT: colorimetric assay that measures the 
reduction of yellow 3-(4,5-dimethythiazol-2-yl)-2,5-di
phenyl tetrazolium bromide (MTT) by mitochondrial 
succinate dehydrogenase 
DMSO: dimethyl sulfoxide 
NAD(P)H: nicotinamide adenine dinucleotide 
phosphate (reduced) 
SENSE: sensitivity encoding for fast MRI 
ROI: region-of-interest 
OCT: optimal cutting temperature 
PCNA: proliferating cell nuclear antigen 
HUVEC: human vascular endothelial cell 
PBS: phosphate buffered saline 
PLA2: phospholipase A2 
VEGF: vascular endothelial growth factor  
TKI: Tyrosine kinase inhibitors 
PI3K: Phosphatidylinositol 3-kinase 
AKT: Protein Kinase B 
mTOR: mammalian target of rapamycin 
mTORC1: mammalian target of rapamycin 
complex 1 
mTORC2: mammalian target of rapamycin 
complex 2 
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